30 closest matches · ranked by relevance
Aerosol Containment · Aerosol Generating Procedure
Primary: Particle Count Measurements During Intubation — 4026; 411; 105; 392 particles/cm^3 — p=<0.001
Protective Device (Physical Object) · Aerosol Disease · Droplet Spread
Primary: Measuring the Time for Performing an Airway Procedure With or Without the Biocontainment Device. — 46; 37 time (seconds)
Transmission, Patient-Professional
Primary: Aerosol Particle Concentrations With Size of 1-3 Micrometer at 1 Foot Away From the Patient — 13000; 11000; 10000; 12000 particles/m3
Surgical Site Infection
Primary: Incidence of Implant Infection (Number of Occurrences in Each Arm). — 4; 0 Participants — p=0.067
Infections · Oral Infection
Primary: Particulate Matter (PM) — 121.3; 135.1; 147.6; 128.4 micrograms per cubic meter (µg/m³)
Covid19
Primary: Number of Bacterial Colony Forming Units (CFUs) — 47.2; 125.3; 70.7; 116.7 bacterial colony forming units (CFUs)
Infectious · Gastro-Intestinal Disorder · Safety Issues
Primary: Aerosolization of Particles During Upper Endoscopy — 9.86; 9.87; 6.93; 7.05 particle count per cubic ft
Surgery
Primary: Surgery Site CFU Density — 7; 11; 0 CFU/cubic meter — p=<0.001
Cystic Fibrosis
Primary: Uniformity of Aerosol Distribution — -0.05; 0.10 ratio — p=0.07
Surgery
Primary: CFU Density — 5.05; 1.55 CFU/m^3
Influenza Virus Infection Transmission in Humans
Primary: Viral Copy Number in 30-minute Exhaled Breath Sample — 38,000; 12,000 Fine aerosol RNA copy number
Surgery
Primary: Surgery Site CFU Density — 3.08; 1.73 CFU/m3
Dyspnea
Primary: Change in Subject Rating of Breathing Discomfort (Dyspnea) Before and After Treatment. — -1.86; -0.61; -0.15 units on a scale — p=0.35
COVID-19
Primary: COVID-19 Contamination Rate. — 2; 5 Participants
Healthy · Dyspnea
Primary: Subject Rating of Breathing Discomfort (Dyspnea) — 20; 20; 16; 17 units on a scale — p=0.99
Respiratory Distress Syndrome, Newborn
Primary: Number of Participants With Adverse Events as a Measure of Safety and Feasibility — 3; 8; 4; 12 Participants
Anesthesia
Primary: End-tidal CO2 Concentration (%) — 5.069; 5.096 % end-tidal CO2
Cystic Fibrosis
Primary: Absorptive Clearance Rate — 42; 32 percentage of DTPA absoprtion per hour
Covid19 · Pneumonia, Viral
Primary: Count of White Blood Cells (WBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With…
Waste Anesthetic Gas (WAG) Emanating From Patients Post-operative Recovery
Primary: Waste Anesthetic Gas Measured by Parts Per Million Within PACU Caregiver's Breathing Zone With Caring for Patients — 60.6; 56.9 parts per million — p=0.24
Respiratory Insufficiency
Primary: Venilator Associated Events (VAE) — 44; 40; 4; 2 Participants
Cystic Fibrosis
Primary: Mean Total Administration Time — 37.0; 16.4; 4.2; 5.0 minutes
Asthma
Primary: Delivered Dose of Fluticasone (on the Filter) — 48; 45; 41; 40 Percent filter dose of fluticasone — p=<0.001
Cystic Fibrosis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 90; 180 participants
Asthma
Primary: AMP Challenge Test PC20 — 79.21; 79.74; 62.69; 92.1 mg/ml
Anesthetic Ventilatory Requirements
Primary: Airway Dead Space With Devices for Heat and Moisture Exchange of Respiratory Gas. — 136 mL
Influenza
Primary: Viral Confirmation — 6; 0 Participants
Respiratory Distress Syndrome in Premature Infant
Primary: Intubation/Cannulation and Instilled Surfactant — 45; 21; 26 Participants — p=0.1924
Pneumonia, Bacterial
Primary: Change From Baseline in Clinical Pulmonary Infection Score (CPIS) For Each Patient, Value Obtained From a Daily Assessment Over the 10 Day Study Period Was Compared to…
Airway Inflammation
Primary: Change From Baseline to 4 Hours in Sputum Percent Neutrophils — -0.04; -0.5 percent neutrophils — p=> 0.99